ArticleAntimicrobial agents and chemotherapy2015
Persister Development by Borrelia burgdorferi Populations In Vitro.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 60 citations in OpenAlex.
- Arresting spirochetes: nonthermal extremely low-frequency electromagnetic field exposure suppressesFrontiers in medicine · 2026Article
- A high-resolution screen identifies a preexisting beta-lactam that specifically treats Lyme disease in mice.Science translational medicine · 2025Article
- Article
- Lactate dehydrogenase is the Achilles' heel of Lyme disease bacteriumbioRxiv : the preprint server for biology · 2025Article
- Genomic characterization and antibiotic susceptibility of biofilm-formingFrontiers in cellular and infection microbiology · 2025Article
- Article
- The Use of Natural Bioactive Nutraceuticals in the Management of Tick-Borne Illnesses.Microorganisms · 2023Review
- Lyme disease and the pursuit of a clinical cure.Frontiers in medicine · 2023Review
- Efficacy of Short-Term High Dose Pulsed Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-Infections: A Report of Three Cases and Literature Review.Antibiotics (Basel, Switzerland) · 2022Article
- Review
- Disulfiram: A Repurposed Drug in Preclinical and Clinical Development for the Treatment of Infectious Diseases.Anti-infective agents · 2022Article
- A Review of Post-treatment Lyme Disease Syndrome and Chronic Lyme Disease for the Practicing Immunologist.Clinical reviews in allergy & immunology · 2022Review
- Extraction and Fractionation of Bioactives fromPharmaceuticals (Basel, Switzerland) · 2022Article
- Recent Progress in Lyme Disease and Remaining Challenges.Frontiers in medicine · 2021Review
- Detecting Borrelia Spirochetes: A Case Study With Validation Among Autopsy Specimens.Frontiers in neurology · 2021Article
- A Quantitative Survey of Bacterial Persistence in the Presence of Antibiotics: Towards Antipersister Antimicrobial Discovery.Antibiotics (Basel, Switzerland) · 2020Article
- Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31.Scientific reports · 2020Article
- A Practical Approach to the Diagnosis of Lyme Borreliosis: From Clinical Heterogeneity to Laboratory Methods.Frontiers in medicine · 2020Review
- Lyme Disease Frontiers: ReconcilingPathogens (Basel, Switzerland) · 2019Review
- Metamorphoses of Lyme disease spirochetes: phenomenon of Borrelia persisters.Parasites & vectors · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Doxycycline is an antibiotic commonly used to treat Lyme disease and other bacterial infections. The MIC and minimum bactericidal concentration (MBC) for Borrelia burgdorferi have been investigated by different groups but were experimentally established in this study as a function of input cell density. We demonstrated that B. burgdorferi treated in the stationary phase has a higher probability of regrowth following removal of antibiotic. In addition, we determined experimentally and mathematically that the spirochetes which persist posttreatment do not have a longer lag phase but exhibit a lower growth rate than untreated spirochetes. Finally, we found that treating the spirochetes by pulse-dosing did not eliminate growth or reduce the persister population in vitro. From these data, we propose that B. burgdorferi persister development is stochastic and driven by slowed growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.